Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0022116 (
ischemia
)
91,303
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Junctophilin-2
(
JP2
), a membrane-binding protein that provides a structural bridge between the plasmalemma and sarcoplasmic reticulum, is essential for precise Ca(2+)-induced Ca(2+) release during excitation-contraction coupling in cardiomyocytes. In animal and human failing hearts, expression of
JP2
is decreased markedly, but the molecular mechanisms underlying
JP2
down-regulation remain incompletely defined. In mouse hearts,
ischemia
/reperfusion injury resulted in acute
JP2
down-regulation, which was attenuated by pretreatment with the calpain inhibitor MDL-28170 or by transgenic overexpression of calpastatin, an endogenous calpain inhibitor. Using a combination of computational analysis to predict calpain cleavage sites and in vitro calpain proteolysis reactions, we identified four putative calpain cleavage sites within
JP2
with three N-terminal and one C-terminal cleavage sites. Mutagenesis defined the C-terminal region of
JP2
as the predominant calpain cleavage site. Exogenous expression of putative
JP2
cleavage fragments was not sufficient to rescue Ca(2+) handling in
JP2
-deficient cardiomyocytes, indicating that cleaved
JP2
is non-functional for normal Ca(2+)-induced Ca(2+) release. These data provide new molecular insights into the posttranslational regulatory mechanisms of
JP2
in cardiac diseases.
...
PMID:Molecular Determinants of Calpain-dependent Cleavage of Junctophilin-2 Protein in Cardiomyocytes. 2606 7